Log in
Register- Requesting data for a publication 📥 ♻️ 🚀 Helmut 2023-02-23 10:46📌
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- Group-by-Treatment Interaction: the final word? Helmut 2024-04-19 01:26
- Group-by-Treatment Interaction: FDA Helmut 2024-09-20 13:30
- Group-by-Treatment Interaction: Rejoinder Helmut 2024-12-17 10:26
- Group-by-Treatment Interaction: the final word? BEQool 2024-10-03 15:09
- ANOVA of Model 1 Helmut 2024-10-03 15:33
- ANOVA of Model 1 BEQool 2024-10-03 16:08
- ANOVA of Model 1 Helmut 2024-10-04 10:11
- Between vs Within mittyri 2024-10-05 00:08
- Between vs Within BEQool 2024-10-06 20:06
- Treatment-by-Group in PROC MIXED and PROC GLM? mittyri 2024-10-06 22:00
- Treatment-by-Group in PROC MIXED and PROC GLM? BEQool 2024-10-07 10:27
- Treatment-by-Group in PROC MIXED and PROC GLM? mittyri 2024-10-07 13:11
- Treatment-by-Group in PROC MIXED and PROC GLM? BEQool 2024-10-14 11:01
- Treatment-by-Group in PROC MIXED and PROC GLM? mittyri 2024-10-07 13:11
- Treatment-by-Group in PROC MIXED and PROC GLM? BEQool 2024-10-07 10:27
- Treatment-by-Group in PROC MIXED and PROC GLM? mittyri 2024-10-06 22:00
- Between vs Within BEQool 2024-10-06 20:06
- Between vs Within mittyri 2024-10-05 00:08
- ANOVA of Model 1 Helmut 2024-10-04 10:11
- ANOVA of Model 1 BEQool 2024-10-03 16:08
- ANOVA of Model 1 Helmut 2024-10-03 15:33
- Group-by-Treatment Interaction: FDA Helmut 2024-09-20 13:30
- Questions about "sequence effect" mentioned in a FDA PSG Darborn 2024-12-10 11:04
- Mixed effects model: ML or REML Mahmoud 2024-12-05 11:20
- Question about computing 90% CI w data from 2 separate studies jag009 2024-10-14 01:44
- Question about computing 90% CI w data from 2 separate studies dshah 2024-10-14 08:38
- Question about computing 90% CI w data from 2 separate studies jag009 2024-10-14 15:40
- Question about computing 90% CI w data from 2 separate studies BEQool 2024-10-14 11:37
- Question about computing 90% CI w data from 2 separate studies jag009 2024-10-14 15:45
- Question about computing 90% CI w data from 2 separate studies BEQool 2024-10-18 12:03
- Question about computing 90% CI w data from 2 separate studies dshah 2024-10-15 06:11
- Question about computing 90% CI w data from 2 separate studies jag009 2024-10-14 15:45
- Question about computing 90% CI w data from 2 separate studies dshah 2024-10-14 08:38
- Standard deviation of different designs BEQool 2024-06-27 12:25
- Standard deviation of different designs Helmut 2024-06-27 13:29
- Standard deviation of different designs BEQool 2024-06-28 07:35
- Standard deviation of different designs ElMaestro 2024-06-29 22:08
- Standard deviation of different designs BEQool 2024-07-01 07:25
- Standard deviation of different designs ElMaestro 2024-07-01 07:38
- Standard deviation of different designs BEQool 2024-07-01 08:41
- Standard deviation of different designs mittyri 2024-07-01 11:18
- Standard deviation of different designs BEQool 2024-07-01 08:41
- Standard deviation of different designs ElMaestro 2024-07-01 07:38
- Standard deviation of different designs ElMaestro 2024-07-03 13:37
- Standard deviation of different designs BEQool 2024-07-01 07:25
- Standard deviation of different designs Helmut 2024-06-27 13:29
- Subject effect justification Dafni_C 2024-01-17 10:00
- Subject effect justification Relaxation 2024-01-17 12:30
- Carry over and statistical adjustment in BE computations Achievwin 2023-10-02 20:34
- Carry-over → 🚮 Helmut 2023-10-02 21:06
- Carry-over → 🚮 Achievwin 2023-10-03 12:13
- Carry-over → 🚮 Helmut 2023-10-03 12:48
- Carry-over dshah 2023-10-03 16:34
- Carry-over Achievwin 2023-10-03 20:33
- Carry-over Helmut 2023-10-04 08:31
- Carry-over Achievwin 2023-10-04 16:38
- Carry-over dshah 2023-10-04 11:22
- Carry-over Helmut 2023-10-04 08:31
- more than 20% subject carry over effect investigation mittyri 2023-10-05 20:15
- carry over effect investigation based on what? Helmut 2023-10-06 07:08
- carry over effect investigation based on what? dshah 2023-10-06 13:20
- Carry-over Achievwin 2023-10-03 20:33
- Carry-over → 🚮 Achievwin 2023-10-03 12:13
- Outdated and wrong answers mittyri 2023-10-05 20:34
- Wrong answer Helmut 2023-10-06 07:19
- Carry-over → 🚮 Helmut 2023-10-02 21:06
- Calculation of PE and 90% CI Brus 2023-06-14 16:34
- No ‘R1’ and ‘R2’ in replicate designs Helmut 2023-06-14 22:26
- No ‘R1’ and ‘R2’ in replicate designs Brus 2023-06-15 14:07
- Rose is a rose is a rose is a rose Helmut 2023-06-15 14:49
- No ‘R1’ and ‘R2’ in replicate designs Achievwin 2023-06-19 19:42
- No ‘R1’ and ‘R2’ in replicate designs Brus 2023-06-15 14:07
- No ‘R1’ and ‘R2’ in replicate designs Helmut 2023-06-14 22:26
- within subject standard deviation in fully replicate design if carry over effect is present Ankit Parikh 2023-06-08 13:54
- within subject standard deviation in fully replicate design if carry over effect is present dshah 2023-06-08 16:35
- within subject standard deviation in fully replicate design if carry over effect is present Ankit Parikh 2023-06-09 07:15
- within subject standard deviation in fully replicate design if carry over effect is present dshah 2023-06-14 09:26
- within subject standard deviation in fully replicate design if carry over effect is present Ankit Parikh 2023-06-14 09:33
- within subject standard deviation in fully replicate design if carry over effect is present dshah 2023-06-14 10:37
- within subject standard deviation in fully replicate design if carry over effect is present Ankit Parikh 2023-06-14 09:33
- within subject standard deviation in fully replicate design if carry over effect is present dshah 2023-06-14 09:26
- within subject standard deviation in fully replicate design if carry over effect is present Ankit Parikh 2023-06-09 07:15
- within subject standard deviation in fully replicate design if carry over effect is present dshah 2023-06-08 16:35
- average bioequivalence: MLE vs. REML Mahmoud 2023-03-11 12:21
- average bioequivalence: MLE vs. REML PharmCat 2023-03-14 20:44
- average bioequivalence: MLE vs. REML Mahmoud 2023-03-15 08:35
- average bioequivalence: MLE vs. REML PharmCat 2023-03-16 23:51
- average bioequivalence: MLE vs. REML Mahmoud 2023-03-15 08:35
- average bioequivalence: MLE vs. REML PharmCat 2023-03-14 20:44
- Variance VS Coefficient of variation Imph 2023-02-27 09:09
- s² ↔ CV Helmut 2023-02-27 13:00
- CV ≈ s for low variances mittyri 2023-02-27 20:45
- CV ≈ s for low variances Helmut 2023-02-28 10:24
- CV ≈ s for low variances Imph 2023-03-06 12:42
- CV ≈ s for low variances Helmut 2023-02-28 10:24
- CV ≈ s for low variances mittyri 2023-02-27 20:45
- s² ↔ CV Helmut 2023-02-27 13:00
- Are Statistical Analysis Plans “required” for Pivotal Studies? Sereng 2023-02-08 18:23
- SAP vs. part of the clinical protocol Helmut 2023-02-09 09:49
- SAP vs. part of the clinical protocol Sereng 2023-02-10 23:34
- Traceability Helmut 2023-02-11 13:22
- SAP vs. part of the clinical protocol Sereng 2023-02-10 23:34
- Are Statistical Analysis Plans “required” for Pivotal Studies? Achievwin 2023-02-15 12:07
- Are Statistical Analysis Plans “required” for Pivotal Studies? ElMaestro 2023-02-16 06:55
- SAP vs. part of the clinical protocol Helmut 2023-02-09 09:49
- Pharmacokinetic and statistical analysis in bioequivalence while maintaining the blind Imph 2023-02-12 08:31
- Blinded NCA in Phoenix/WinNonlin Helmut 2023-02-12 08:45
- Blinded NCA in Phoenix/WinNonlin Imph 2023-02-12 09:08
- Blinded NCA in Phoenix/WinNonlin Helmut 2023-02-12 09:21
- Blinded NCA in Phoenix/WinNonlin Imph 2023-02-12 09:08
- Pharmacokinetic and statistical analysis in bioequivalence while maintaining the blind ElMaestro 2023-02-13 15:07
- Phoenix: Locked Workflows Helmut 2023-02-13 16:08
- Phoenix: Locked Workflows Imph 2023-02-14 13:51
- Blind forever? Helmut 2023-02-14 14:00
- Blind forever? Imph 2023-02-15 11:00
- Blind forever? Helmut 2023-02-14 14:00
- Phoenix: Locked Workflows Imph 2023-02-14 13:51
- Phoenix: Locked Workflows Helmut 2023-02-13 16:08
- Blinded NCA in Phoenix/WinNonlin Helmut 2023-02-12 08:45
- How to calculate Within-subject variability in a replicated BE Brus 2022-12-25 09:21
- Models, models! Helmut 2022-12-25 12:17
Ing. Helmut Schütz